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ABBREVIATION
FES Functional electrical stimulation
AIM To assess the effect of functional electrical stimulation (FES) of ankle dorsiflexors in
children and adolescents with spastic cerebral palsy (CP) during walking.
METHOD A systematic review was performed using the American Academy of Cerebral Palsy
and Developmental Medicine methodology and the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines. Six databases were searched for studies
applying interventions to patients aged younger than 20 years. Outcomes were classified
according to the International Classification of Functioning, Disability and Health (ICF).
RESULTS Seven hundred and eighty abstracts were found, 35 articles were fully screened,
and 14 articles were used for analysis. Only five articles (three studies) were of level I to III
evidence. At ICF participation and activity level, there is limited evidence for a decrease in
self-reported frequency of toe-drag and falls. At ICF body structure and function level, there
is clear evidence (I–III) that FES increased (active) ankle dorsiflexion angle, strength, and
improved selective motor control, balance, and gait kinematics, but decreased walking speed.
Adverse events include skin irritation, toleration, and acceptation issues.
INTERPRETATION There are insufficient data supporting functional gain by FES on activity
and participation level. However, evidence points towards a role for FES as an alternative to
orthoses in children with spastic CP.
Cerebral palsy (CP) is the most common cause of motor
disability in children, with an incidence of 2.11 children
per 1000 births in Europe.1 According to the current defi-
nition, CP describes a group of permanent disorders of the
development of movement and posture, causing activity
limitations and resulting from an injury in the developing
central nervous system.2–4
For classifications of severity of CP, the International
Classification of Functioning, Disability and Health (ICF)
can be used to distinguish different levels.5 At the level of
body functions and structures, the anatomical distribution
(e.g. unilateral and bilateral) and the motor abnormality
(i.e. spastic, dyskinetic, or mixed) is important for this sys-
tematic review. At the level of activity and participation,
the Gross Motor Function Classification System (GMFCS)
is used.6 This review focuses on walking children with
spastic CP.
Spasticity and treatment options
Spasticity is defined as a velocity-dependent increase in the
tonic stretch response with excessive tendon jerk reflexes; it
is caused by the reduction of inhibitory impulses on lower
motoneurons.7 Spasticity often interferes with mobility,
especially with walking. Spasticity of the ankle plantar-flex-
ors, and weakness and poor selective control of the ankle
dorsiflexors (such as the anterior tibial muscle), can lead to
drop foot or true equinus.8 As a result, patients with CP
often have a decreased walking distance (fatigue) and
increased incidence of tripping and falling. Ankle-foot
orthoses are frequently used to support weakened muscles
but they can restrict active motions and thereby exacerbate
muscle weakness.9
Functional electrical stimulation
Functional electrical stimulation (FES) is defined as ‘the
electrical stimulation of muscles that have impaired motor
control to produce a contraction to obtain functionally
useful movement’.10 Two types of FES can be distin-
guished: (1) direct stimulation of the anterior tibial muscle
through motor points or (2) stimulation of the fibular (for-
merly called peroneal) nerve, namely indirect stimulation
of the anterior tibial muscle, other (toe-)extensors and the
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fibular muscle group. The fibular muscle group primarily
everts the foot and partly contributes to plantar-flexion.11
FES might function as a dynamic functional orthosis.12
The mechanism is based on depolarization of the axon by
an electrical field. A bidirectional action potential, activat-
ing the motor unit, is created if the speed and intensity of
the electrical field is sufficient. Direct depolarization of
muscle fibres is also possible, but this requires 10 to 100
times the amount of current.13 FES in drop foot is used to
stimulate the common peroneal nerve, activating the dorsi-
flexor muscles of the foot during the swing phase of gait.
FES stimulus parameters
The stimulus waveform used for FES can either be
monophasic or biphasic. The difference is the net move-
ment of charged ions, which is present in monophasic but
absent in biphasic waves. The biphasic waveform is pre-
ferred, because this rapid changing of stimulus polarity
decreases skin irritation and increases comfort. The current
amplitude is an important factor in the safety and comfort
of FES. Pulse width (or phase duration) indicates the
length of each phase. Either the pulse width or the ampli-
tude should reach the threshold to create an action poten-
tial. A smaller pulse width causes less discomfort and skin
irritation. The pulse rate (or frequency) of the stimulation
determines the rate of nerve depolarization and influences
the type of muscle contraction: twitch contractions occur-
ring at low (1–10 pulses per second [pps or Hz]) frequency;
or incomplete tetanic or fused tetanic contractions at
higher frequencies (15–25 or >45–50pps). Charge per
phase is calculated as the current–time integral. As the
phase charge increases, more nerve fibres are excited. The
interpulse interval can be constant or can be manipulated.
Manipulation can sometimes lead to more force production
and less fatigue, and therefore interrupted pulses are com-
mon in rehabilitation applications.
Aim of the study
This systematic review focuses on FES of the ankle dorsi-
flexors in children with spastic CP during walking. As
previously stated, increased fatigue, falling, and tripping
are the most common clinical problems. Despite several
published studies on FES, consensus for clinical practice
is lacking.14 The aims of this systematic review are the
following: (1) to assess the effect of FES of the ankle
dorsiflexors and level of evidence on outcomes at ICF
activity and participation level (e.g. fatigue, falling, and
tripping) and ICF body functions and structures level
(e.g. orthotic effect, gait, force, and spasticity); (2) to pro-
vide a practical guidance for stimulus parameters; and (3)
to provide an overview on side effects of FES of the
ankle dorsiflexors.
METHOD
This systematic review was conducted according to the
American Academy of Cerebral Palsy and Developmental
Medicine methodology for developing a systematic review
of treatment interventions15,16 and the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines.17 Since human participation was not
required for this study, ethical approval did not apply. For
interpretation of all the results, a p-value of ≤0.05 was con-
sidered statistically significant.
Search strategy
A systematic literature search was performed using the fol-
lowing databases: PubMed/MEDLINE (391 articles),
Embase (270 articles), the Physiotherapy Evidence Data-
base (PEDro, 89 articles), Web of Science (308 articles),
CINAHL (94 articles), and the Cochrane Library (58 arti-
cles).
The search strategy included terms describing the popu-
lation (‘cerebral palsy’ or ‘cerebral palsy’ [Medical Subject
Headings, MeSH]) and terms describing the intervention
(‘functional electrical stimulation’ OR ‘fes’ OR ‘neuropros-
thesis’ OR ‘stimulat* foot drop’ OR ‘walkaide’ OR ‘walk
aide’ OR ‘neurostimulat* OR ‘electrical stimulation’). The
searches were updated to 31 December 2015.
Operational definition of population and intervention
(inclusion criteria)
We included studies that described the effects of FES
intervention to the ankle dorsiflexors, producing a muscle
contraction and applied during walking. This intervention
had to be applied to patients with spastic CP younger than
20 years, in a GMFCS level from I to III. Studies on the
described intervention applied after injection of botulinum
neurotoxin A (BoNT-A) were also included but separated
from the studies without BoNT-A injection. We did not
exclude studies based on type of electrical stimulation
before reading full texts, because of the inconsequent use
of terms.
Exclusion criteria
Articles were excluded if (1) they did not report data about
electrical stimulation, (2) the patients included were not
diagnosed with CP, (3) the electrical stimulation interven-
tion applied in the study was not aimed at the ankle dorsi-
flexors, (4) the patients were older than 20 years of age at
the moment of the electrical stimulation intervention, (5)
the article was not a study report, but, for example, a let-
ter, a conference abstract, or study protocol, or (6) the arti-
cle was not available in English, Dutch, or German.
If full-text reading led to the conclusion that the type of
electrical stimulation studied was not FES, the article was
also excluded. Articles lacking details of stimulation param-
eters of the FES device were excluded.
What this paper adds
• Effects of functional electrical stimulation (FES) point towards a potential role
as an alternative to orthoses for patients with spastic cerebral palsy (CP).
• Some evidence for a decrease in self-reported frequency of toe-drag and
falls with the use of FES in spastic CP.
• Limited evidence for improvements in activity and participation in patients
with spastic CP using FES.
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Organization of the evidence and data extraction
Grading of the articles and data extraction was indepen-
dently done by two authors (IM and RJV). Table SI (on-
line supporting information) explains the levels of evidence
used in this systematic review. These levels are based on a
hierarchy of the types of research design. The conduct of
studies was judged using the items in Table SII (online
supporting information). These first two tables are double:
part (a) for group design studies and part (b) for single-
subject design studies. Table SIII (online supporting infor-
mation) provides a summary of all the included articles.
The results of each study were classified by ICF compo-
nent and included in the evidence table (Table SIV, online
supporting information). Both results from level I to III
studies and level IV to V studies are included because of
the small amount of level I to III studies. Results with level
I to III evidence are marked with an asterisk (*). The evi-
dence tables distinguish ‘orthotic’ from ‘therapeutic’ effects
of FES. Immediate correcting effects of FES therapy are
labelled ‘orthotic’, i.e. the difference between walking with
FES and walking without FES. Long-term, persisting
effects are labelled ‘therapeutic’. A summary of the
reported adverse events is reported as Table SV (online
supporting information).
RESULTS
Retrieved articles
A total of 780 articles were identified. These 780 titles and
abstracts were screened by two authors. Seven hundred
forty articles were excluded because of the exclusion crite-
ria. Five articles were unavailable, even after contacting the
authors. The full text of the remaining 35 articles was read
and the type of electrical stimulation was determined. Sub-
sequently, 13 articles were excluded because the applied
electrical stimulation method was not FES (six studies
applied neuromuscular electrical stimulation, four studies
applied threshold electrical stimulation, and three applied
stimulation at sensory level).15,18–30 Two articles lacking
data about FES separately to the ankle dorsiflexors were
also excluded.31,32 Five other excluded articles were reviews
about FES of different muscles14,33–36 and two articles
were excluded because they did not report specific infor-
mation sufficiently or were only conference abstracts
instead of full-text articles.37,38 A secondary search, consist-
ing of checking the reference lists of the included articles,
yielded one useful article.39 Finally, 14 articles were
included, which reported about 11 original studies. Two of
these articles11,40 did not describe the type of CP of the
participants; for one article this problem was resolved by
contacting the authors,11 but both articles were finally
included.
Patients and outcomes
In total, 127 patients received FES of the ankle dorsiflexors
(14 bilaterally affected and 113 unilaterally affected). The
ages of the participants ranged from 5 to 19 years and the
GMFCS levels from I to III.
In three studies, percutaneous electrodes were used to
provide FES. One of these three studies compared percuta-
neous with surface electrodes. The distinction between
nerve and motor point stimulation was not clear. Most
studies applied electrodes on both the nerve and the mus-
cle belly, looking for the best response. Overall the use of
tilt sensors was more common than the use of foot sensors.
To control the timing of FES, seven (out of 11) studies
used footswitches, and four (out of 11) used a tilt sensor.
One study investigated the combination of FES with
BoNT-A treatment. For details see Table SIII.
Different methods were used to measure outcomes: gait
analysis, questionnaires, and clinical measurements and
scales. The effect on angle of ankle dorsiflexion was inves-
tigated most frequently. A description of the results follows
in the next paragraph. For detailed results see Table SIV,
which provides effect, effect size, and the involved ICF
component for each outcome per study. It is organized on
outcome of interest and type of effect (orthotic versus ther-
apeutic).
Reported adverse events include skin problems and
acceptation issues. For details see Table SV which shows
the reported information about adverse events.
To assess the effect of FES of the ankle dorsiflexors
At ICF activity and participation level
Evidence level I to III studies. Four articles with level I to
III evidence reported outcomes.10,39,41,42 Pool et al.
reported a decrease in the self-reported frequency of toe-
drag (statistically significant) and falls (non-significant).41
They also reported (mostly statistically significant)
improvements in self-perceived performance and satisfac-
tion.39 Meilahn et al. reported undertaking of a variety of
physical activities while wearing the stimulator. The most
frequent participation was in bicycling and running.43 The
included studies provided evidence that FES was compati-
ble with daily life: Meilahn et al. found that, at different
time points, 71% to 89% of the participants preferred FES
over treatment with ankle–foot orthoses,43 and Prosser
et al. reported that 86% of the participants chose to con-
tinue FES treatment.11 No data were available for fatigue.
Pool et al. reported an improved balance and mobility
using the community-based balance and mobility score;44
in addition, they reported improvement of dynamic step-
ping.41 These outcomes were considered activity compo-
nents, because of the type of measurement.44,45 None of
the included studies reported detailed results in the partici-
pation domain.
At ICF body function and structures level
Evidence level I to III studies. Four articles with level I to
III evidence reported outcomes of FES therapy on the
domain of body function and body structure.10,41,42,46
Three studies reported an orthotic improvement (i.e. more
dorsiflexion) in ankle dorsiflexion at two moments of the
gait cycle: initial contact and peak angle in swing.10,41,46
Van der Linden et al. reported an orthotic improvement
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using the Gillette Gait Index.10,47 They also showed a sta-
tistically significant orthotic decrease in walking speed,
although others reported a non-significant increase.10,41,46
Because walking speed was measured in laboratorial set-
tings, it was interpreted as a body function component,
because it might not be representative of the walking speed
in daily life. Pool et al. reported a significant orthotic
increase in step length (for the affected leg).41 Data on
ankle absorption work were not conclusive.46 No statisti-
cally significant change in passive ankle dorsiflexion range
of motion was reported.10,41 Pool et al. reported a thera-
peutic increase in ankle dorsiflexion strength (both hand-
held dynamometry and functional strength, measured as
maximum number of heel raises) and in selective motor
control.42 They also reported a probable therapeutic
decrease in gastrocnemius spasticity.41
Van der Linden et al. reported an increase in functional
walking ability.10,48 However, most of these results did not
reach statistically significance.
Pool et al. showed a strong positive relation between
ankle dorsiflexion strength and selective motor control.42
No relation between anterior tibial or anterior compart-
ment muscle volume and ankle dorsiflexion strength was
found.42
Level IV to V studies. Four articles added outcomes for the
angle of active ankle dorsiflexion, measured at different
moments in the gait cycle (initial contact, mid-swing, or at
toe-off) at different velocities (fast or normal walking
speed). These outcomes showed (partly statistically signifi-
cant [six out of 11 measurements]) improvement.11,43,49,50
Postans et al. reported a statistically significant orthotic
improvement in foot contact pattern, a parameter that was
not reported in level I to III studies.49 For the therapeutic
effect of FES on the foot contact pattern, no p-values were
reported for the two measurements showing a slight trend
of detoriation.51
Data on cadence (steps per minute) and ankle generation
work were not conclusive.11,40,52
Pool et al. (levels IV–V) reported a non-significant
change in gait pattern using the Observational Gait
Scale.9,53
FES as add-on treatment with BoNT-A. In this systematic
review, one level IV study on the effects of FES of the
anterior tibial muscle after BoNT-A therapy of the antago-
nist (gastrocnemius muscle) was included. Van Galen et al.
reported a therapeutic increase in the angle of ankle dorsi-
flexion at the end of the swing phase and a trend of thera-
peutic improvement in foot contact pattern (without p-
values for the latter parameter).54 The increase in active
ankle dorsal flexion in the post-BoNT-A phase was not as
large as in the post-FES and post-control phases. This
could imply a reinforcing effect of these two treatments on
each other.
What is the strength of the evidence?
Five included articles with evidence at level IV9,11,49,51,54
hint at causal inferences, while four level V studies40,43,50,52
only suggest the possibility of causal inferences. On the
basis of the five remaining articles, which are based on two
group design studies of level II10,39,41,42 and one single-
subject design study of level I,46 it can be concluded that
the outcomes are attributable to FES.
The quality of conduct of the studies mostly ranged
from moderate to weak. For the level II group design
studies included in this review, the quality of conduct
was moderate.10,39,41,42 In these studies the outcome
assessors were not (completely) masked and only one of
the studies reported a power calculation.42 The quality
of conduct of the single-subject design studies was mod-
erate to weak, because most of the studies did not assess
interrater or intrarater reliability of measures, the out-
come assessors were not unaware of the phase of the
study, no stability of the data was demonstrated in the
baseline, the type of single-subject design study was not
stated, and the authors did not apply statistical analysis.
The study of Pool et al. had a strong quality of con-
duct.9
To provide a practical guidance for stimulus parameters
The parameter settings of FES showed a broad range of
characteristics in the electrical field and in timing. There
were no results reported on the relation between parameter
setting of FES and the clinical effect. See Tables I and SIII
for a summary of stimulation parameters.
What kinds and magnitudes of adverse events were
documented?
Eight articles documented some information on adverse
events with FES therapy.9,10,39,41–43,49,51 Known adverse
events include poor tolerance of stimulation and skin prob-
lems. Pool et al. performed (skin) checks every 1 to
2 weeks for adverse events and did not find skin prob-
lems.9,41,42 The remainder of the studies relied on report-
ing of adverse events by participants or the parents, namely
by questionnaires and surveys or the recording of answers
by a device. Meilahn et al. reported skin irritation in 20%
of the participants.9 Postans et al. found poor tolerance of
stimulation in 27% of the participants.49
Table I: Characteristics of functional electrical stimulation
Parameter Characteristics
Stimulus waveform Monophasic or
biphasic
Current amplitude (calculation for biphasic
waves = root-mean-square current)
20–100mA
Pulse width 3–350ls
Pulse frequency
Twitch contractions 1–10Hz
Incomplete tetanic 15–25Hz
Fused tetanic contractions >45–50Hz
Clinical range 16.7–50Hz
Charge per phase (current–time integral) 0.06–35mC
Interpulse interval (constant or interval) 0.2–0.3s
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Since most of the included studies excluded patients with
(uncontrolled) epileptic seizures and/or cardiac conditions,
no evidence can be provided about the risks to these
patients when using FES. Reported adverse events included
embarrassment and ‘not wanting to wear FES at school’,
besides practical issues such as improper fit and bulkiness
of the cuff and problems with the electrodes and
wires.10,39,43,51
DISCUSSION
To our knowledge, this is the first systematic review
addressing the clinical application of FES of the ankle dor-
siflexors at the ICF levels of activity and participation, and
body structure and function.
Activity and participation level
None of the available studies really addressed the effect of
FES at the activity and participation level. Of course, the
decreased incidence of toe-drag and falling might indirectly
point towards less interference with normal daily activities
such as playing and running.41 Decreased distance of walk-
ing as result of fatigue was not addressed in the assessed
studies. Available data on walking only addressed instru-
mented walking in a gait laboratory. The preference of
patients to continue using FES (instead of orthoses) might
indirectly point towards a better acceptance in daily
life.11,43 Lastly, improvements in self-perceived perfor-
mance and satisfaction were reported.39 Nevertheless, the
reported information does not make it possible to assess
the effect of FES on participation.
Body and function level
One of the reasons for using FES might be as an alterna-
tive to conventional orthoses. Therefore, most studies
aimed at outcome measures describing the orthotic effect
of FES.
Indeed, it was consistently shown that FES increased
the angle of active ankle dorsiflexion, and improved gait
kinematics, selective motor control, and balance.10,41,42
Data on the effect of FES on gait velocity were some-
what contradictory.10,41,46 However, the main finding was
a decreased or unchanged walking speed. This is in line
with the results of Winter et al., who concluded that
gait velocity is under control of the plantar-flexors (for
push-off), hip-flexors (for pull-off), knee extensors (dur-
ing late stance), and the knee flexors (during late
swing).55
Interestingly, it was found that FES increased ankle
dorsiflexion strength.9,42 This result might be seen as a
therapeutic effect of FES. In addition, these data are sup-
ported by volume increases in muscles using ultrasound
and by experimental data showing FES-induced changes
in muscles (morphologically and physiologically). Another
body of evidence suggests modification of the afferent
input of depressed body segments, thereby helping these
segments in the competition for cortical representa-
tion.13,56 This might promote adaptive changes in cortical
connectivity,57 which could be responsible for the carry-
over effect.
However, it is questionable whether the improvement of
strength can be generalized, since Pool et al. showed a cor-
relation between selective motor control and force; there-
fore selection of patients might be important.
The effect of FES on gastrocnemius spasticity is intrigu-
ing. It can be speculated whether antagonist stimulation of
the spastic muscle might inhibit the spasticity by reciprocal
inhibition.12 Consequently, the active ankle dorsiflexion
angle might increase. However, this finding needs the fur-
ther support of studies aimed at proving this concept.
FES and BoNT-A: synergism?
Possible mechanisms for the synergism of FES and
BoNT-A are the spread of BoNT-A by activity of the
muscle (induced by FES) and the reciprocal inhibition of
the antagonist during activation of the agonist, as men-
tioned before.58 Furthermore, the combination of
BoNT-A therapy of the gastrocnemius muscle and FES
of the ankle dorsiflexors tackles both the plantar-flexor
spasticity and the dorsiflexor weakness, instead of con-
centrating on only one aspect. However, this topic needs
an additional long-term prospective study to confirm
these effects.
Grading of the evidence: limitations
As summarized in the Results, the level of evidence and
quality of the studies in this topic are moderate. Because
most (nine out of 14) of the included studies were level IV
to V studies, we decided to include their results in the dis-
cussion of the parameters that were not represented in the
level I to III studies.
Stimulus parameter guidance
On the basis of the existing evidence, we provide an over-
view of the FES parameters used (Table I). However, evi-
dence for the relation between parameter setting and effect
(orthotic and therapeutic) or side effects is currently lack-
ing. Therefore, we are not able to provide clinical guidance
for FES parameter settings.
Side effects
Part of the included studies reported information on side
effects. Skin irritation and tolerance problems are most fre-
quently reported. Decreased skin tolerance and discomfort
may be more common with surface electrodes than with
percutaneous electrodes.40,59 Yet the included studies pro-
vided no evidence about this, since they all reported
adverse events using surface electrodes. It is possible that a
4-week ‘accommodation phase’ to adapt to FES helps to
increase tolerance.11
Patients with (uncontrolled) epileptic seizures and/or
cardiac conditions were not included in the patient popula-
tion. Hypothetically, the current applied by FES can travel
throughout the body by way of the ionized body fluids,
and subsequent side effects may occur.12
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Despite the adverse events and some acceptation issues,
the experience of patients seems to be good. This positive
experience is supported by the percentage of patients con-
tinuing FES treatment (71%–89%).11,43
CONCLUSION AND FUTURE DIRECTION
From the current evidence, it cannot be concluded that
FES (of the ankle dorsiflexors) improves functioning at the
activity and participation level. However, current evidence
supports the potential role of FES as an alternative to clas-
sic orthotic treatment. On the basis of the current evi-
dence, no guideline can be provided for treatment intensity
(e.g. hours per day), stimulator settings, and types of elec-
trode. Side effects of FES are common (skin irritation) but
do not seem to interfere with satisfaction and continuation,
although data on side effects are limited.
Future studies should especially pay attention to the
domain of activity and participation.
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